Literature DB >> 19806381

[Visual self-assessment with the ACTO test during follow-up of AMD patients after intravitreal injections].

A Cordes1, A Strobel, C H Meyer, F Ender, N Schrage.   

Abstract

INTRODUCTION: Monthly controls are necessary after injections of vascular endothelial growth factor (VEGF) to enable timely recognition of a renewed decrease in vision. However, these monthly control intervals are not realistic for many older patients with age-related macular degeneration (AMD), and outpatient clinics often reach their logistical limits because of inadequate funding for the additional medical work. Against this background, we conceived the ACTO self-test as a novel screening method for patients to discover unnoticed visual changes outside the routinely scheduled ophthalmic examination.
MATERIAL AND METHODS: The paper version of the ACTO self-test consists of a reading chart gradated in decimal steps as well as six questions regarding the quality of the Amsler grid. The patient uses a self-screening test to examine each eye separately and then transfers the results to a table. Along with the self-examination, the Action Eyesight Service Center is available to the patient by phone to motivate the patient and schedule a new appointment if improved test results occur. If decreased values or suspected decreased visual function occur, these are verified immediately by the referring physician.
RESULTS: There is a good correlation between the steps of the ACTO self-test and standard visual acuity at 4 m (r(2)=0.9). Altogether, 1,444 patients were followed by phone and 745 participated in repeated regular audits, for a total of 3,003 phone contacts. The treating physician was informed about decreased visual acuity or increased Amsler distortion in the ACTO test in 137 cases, and immediate verification was done. We had 699 dropouts; the reasons were decreased visual acuity below the limits of the ACTO test in 39%, additional monthly examinations by the local ophthalmologist in 29%, and a desire for no more telephone follow-up (despite initial written consent) in 32%. Decreased vision when reading or an increased score on the Amsler test within the ACTO screening test was observed in 18% of AMD patients during the maintenance phase.
CONCLUSION: Monthly screening by the ACTO screening test in combination with phone audits offers a new way to test visual acuity, with the Amsler score helping to detect changes in visual function. For patients with visual changes, confirmation by the ophthalmic physician can be achieved in time. Self-assessment cannot replace qualified ophthalmologic examination, but monthly self-controls enhance safety, reduce the number of physician contacts, and improve the detection of visual changes, with the option of immediate ophthalmic retreatment.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19806381     DOI: 10.1007/s00347-009-1959-4

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  23 in total

1.  Transparency of information on eye diseases on the internet.

Authors:  Marc Lüchtenberg; Christian Ohrloff; Rainer Schalnus
Journal:  Ophthalmologica       Date:  2008-12-19       Impact factor: 3.250

2.  Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration.

Authors:  David S Boyer; Andrew N Antoszyk; Carl C Awh; Robert B Bhisitkul; Howard Shapiro; Nisha R Acharya
Journal:  Ophthalmology       Date:  2007-02       Impact factor: 12.079

3.  [Intraocular pressure self-monitoring in glaucoma patients].

Authors:  J Draeger
Journal:  Klin Monbl Augenheilkd       Date:  1998-07       Impact factor: 0.700

4.  Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

Authors:  David M Brown; Peter K Kaiser; Mark Michels; Gisele Soubrane; Jeffrey S Heier; Robert Y Kim; Judy P Sy; Susan Schneider
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

5.  [The Freiburg Vision Test. Automated determination of visual acuity].

Authors:  M Bach
Journal:  Ophthalmologe       Date:  1995-04       Impact factor: 1.059

6.  [Vision test program for ophthalmologists on Apple II, IIe and IIc computers].

Authors:  C Huber
Journal:  Klin Monbl Augenheilkd       Date:  1985-03       Impact factor: 0.700

7.  [Diurnal variation of ocular pressure in open-angle glaucoma with telemonitoring].

Authors:  S Antal; C Jürgens; R Grossjohann; F H Tost
Journal:  Klin Monbl Augenheilkd       Date:  2009-03-17       Impact factor: 0.700

8.  [Intravitreal injections of medications in Germany. Contract situation and legal conditions].

Authors:  F Ziemssen; P Wiedemann; A Kampik; F Holz; K U Bartz-Schmidt
Journal:  Ophthalmologe       Date:  2009-05       Impact factor: 1.059

9.  A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study.

Authors:  Geeta A Lalwani; Philip J Rosenfeld; Anne E Fung; Sander R Dubovy; Stephen Michels; William Feuer; Janet L Davis; Harry W Flynn; Maria Esquiabro
Journal:  Am J Ophthalmol       Date:  2009-04-18       Impact factor: 5.258

10.  Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans.

Authors:  Tim U Krohne; Nicole Eter; Frank G Holz; Carsten H Meyer
Journal:  Am J Ophthalmol       Date:  2008-07-17       Impact factor: 5.258

View more
  1 in total

1.  [Healthcare "Apps" for Smartphones : Relief or toy for patients and the visual impaired?].

Authors:  C H Meyer; B V Stanzel; S Moqaddem; D Brohlburg
Journal:  Ophthalmologe       Date:  2012-01       Impact factor: 1.059

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.